Selank 5mg

Selank 5mg  The Russian Nootropic Peptide for Anxiety Relief, Cognitive Enhancement, and Stress Resilience

Selank 5mg is a synthetic heptapeptide nootropic developed by the Institute of Molecular Genetics of the Russian Academy of Sciences and the Zakusov Institute of Pharmacology. Based on the endogenous neuropeptide tuftsin — a tetrapeptide known for its immunomodulatory properties — Selank was engineered with a stabilising C-terminal extension to improve its metabolic stability and extend its duration of action in biological systems. Over decades of Russian clinical and preclinical research, Selank has demonstrated a remarkable and uniquely balanced pharmacological profile: it delivers significant anxiolytic (anti-anxiety) effects without sedation, enhances cognitive performance and working memory, modulates the immune system, and supports the brain’s stress response mechanisms — all without the dependency, withdrawal, or side-effect burden associated with conventional anxiolytics such as benzodiazepines.

What Is Selank 5mg?

Selank is a synthetic analogue of the endogenous immunomodulatory tetrapeptide tuftsin, extended with a Pro-Gly-Pro sequence to improve enzymatic stability. Its full amino acid sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro. This seven-amino-acid heptapeptide was developed specifically to address anxiety disorders and cognitive deficits in a clinical setting, and it has been approved in Russia and Ukraine as a pharmaceutical drug for the treatment of generalised anxiety disorder (GAD), asthenia, and phobic neuroses under the trade name Selank.

What distinguishes Selank from conventional psychiatric medications and from other research peptides is its dual nootropic-anxiolytic profile. Most anxiolytic compounds — particularly benzodiazepines, barbiturates, and even buspirone — achieve anxiety reduction at the cost of cognitive impairment, sedation, or motor function disruption. Selank achieves anxiety relief while simultaneously enhancing memory consolidation, attention, focus, and learning capacity. This combination is exceptionally rare in psychopharmacology and forms the scientific foundation of Selank’s growing international research interest.

Each vial of Selank 5mg contains a precisely dosed lyophilized heptapeptide, manufactured under controlled conditions to ensure purity, sequence accuracy, and consistent bioactivity. It is typically reconstituted and administered via subcutaneous injection or intranasally, the latter being common in approved clinical applications.

Mechanism of Action — How Selank 5mg Works in the Brain

GABAergic System Modulation

The primary anxiolytic mechanism of Selank involves modulation of the GABAergic system — the brain’s primary inhibitory neurotransmitter network. GABA (gamma-aminobutyric acid) reduces neuronal excitability across the central nervous system, producing calming and anxiety-reducing effects. Selank has been shown to increase GABA-A receptor sensitivity and upregulate GABAergic transmission in key limbic system structures including the hippocampus and amygdala — the brain regions most critically involved in anxiety and fear processing. Critically, Selank’s GABAergic modulation occurs via an allosteric mechanism distinct from benzodiazepine binding sites, which is why it does not produce sedation, tolerance, or physical dependence.

Serotonergic and Dopaminergic Modulation

Selank influences monoaminergic neurotransmission in ways that contribute to both its anxiolytic and cognitive-enhancing effects. Research has demonstrated that Selank increases serotonin metabolism in the cerebral cortex and hippocampus, supporting mood stability and emotional resilience. Simultaneously, Selank modulates dopaminergic activity in the prefrontal cortex — the brain region responsible for executive function, working memory, and cognitive control — which accounts for its observed improvements in focus, motivation, and mental clarity. This balanced monoaminergic influence distinguishes Selank from agents that manipulate a single neurotransmitter system in isolation.

BDNF Upregulation and Neuroplasticity

One of Selank’s most scientifically compelling mechanisms is its ability to increase the expression of Brain-Derived Neurotrophic Factor (BDNF) — a critical neurotrophin responsible for neuronal survival, synaptic plasticity, long-term potentiation (LTP), and the formation of new memories. BDNF is often described as Miracle-Gro for the brain, and its deficiency is strongly implicated in depression, anxiety disorders, cognitive decline, and neurodegenerative diseases. By upregulating BDNF expression, Selank supports the neuroplastic processes that underlie learning and memory consolidation, while simultaneously providing a neuroprotective buffer against stress-induced neuronal damage.

Enkephalin Degradation Inhibition

Selank has been identified as an inhibitor of enkephalin-degrading enzymes — specifically, it reduces the activity of neprilysin and other neutral endopeptidases responsible for breaking down endogenous enkephalins. Enkephalins are endogenous opioid peptides that play important roles in pain modulation, stress regulation, and mood stabilisation. By slowing their enzymatic degradation, Selank extends the half-life and biological activity of endogenous enkephalins, contributing to its anxiolytic and mood-enhancing effects through an endogenous opioidergic mechanism — without the risks associated with exogenous opioid receptor agonists.

Immunomodulatory Activity via the Tuftsin Scaffold

Because Selank is derived from tuftsin — a peptide known for stimulating macrophage activity, natural killer cell function, and T-lymphocyte proliferation — it inherits and extends these immunomodulatory properties. Research has demonstrated that Selank modulates the expression of interleukins and other cytokines involved in immune surveillance, with particularly notable effects on

IL-6 regulation. This immunomodulatory dimension makes Selank unique among nootropic peptides and is especially relevant in the context of stress-induced immune suppression, where chronic anxiety and psychological stress depress immune function over time.

Key Benefits of Selank 5mg

1. Potent Anxiolytic Effects Without Sedation or Dependence

Selank’s most clinically established benefit is its ability to significantly reduce anxiety — including generalised anxiety, social anxiety, phobic responses, and performance-related stress — without producing sedation, cognitive blunting, or physical dependence. In Russian clinical trials comparing Selank to the benzodiazepine phenazepam, Selank demonstrated comparable anxiolytic efficacy while producing none of the sedation, psychomotor impairment, or dependence risks associated with the benzodiazepine. This makes it an exceptionally valuable research compound for non-sedating anxiety intervention.

2. Cognitive Enhancement — Memory, Focus, and Learning

Selank consistently enhances several dimensions of cognitive performance in research settings. Users and research subjects report improvements in working memory capacity, attention span, information processing speed, and the ability to consolidate new information into long-term memory. These effects are mediated through BDNF upregulation, dopaminergic modulation in the prefrontal cortex, and enhanced GABAergic tone that reduces the neurological noise created by anxiety — allowing the brain to operate with greater clarity and efficiency. Unlike stimulant-based nootropics, Selank’s cognitive enhancement does not come with overstimulation, jitteriness, or post-dose cognitive fatigue.

3. Stress Resilience and HPA Axis Regulation

Chronic psychological stress dysregulates the hypothalamic-pituitary-adrenal (HPA) axis, leading to elevated cortisol levels, impaired hippocampal neurogenesis, disrupted sleep, and progressive immune suppression. Selank has demonstrated the ability to modulate HPA axis reactivity, blunting the cortisol stress response without eliminating healthy adaptive stress signalling. This adaptogenic-like effect supports long-term stress resilience, preserves hippocampal integrity under chronic stress conditions, and helps prevent the neurological and immune consequences of prolonged stress exposure.

4. Mood Stabilisation and Emotional Regulation

By simultaneously modulating serotonin metabolism, GABAergic tone, endogenous enkephalin activity, and BDNF expression, Selank produces a broad and balanced mood-stabilising effect. Research subjects and clinical patients treated with Selank report a reduction in emotional reactivity, irritability, and negative rumination, alongside improvements in overall emotional stability, motivation, and subjective sense of wellbeing. These effects emerge without the emotional blunting or anhedonia sometimes associated with serotonin reuptake inhibitors, making Selank’s mood profile distinctly more natural and balanced.

5. Neuroprotection and Anti-Neuroinflammatory Effects

Neuroinflammation — driven by activated microglia and elevated pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 — is a central

mechanism in depression, anxiety disorders, cognitive decline, and neurodegenerative disease. Selank has been shown to reduce neuroinflammatory markers and modulate microglial activation, providing a neuroprotective environment that preserves neuronal integrity under conditions of stress, toxin exposure, or ischaemia. This anti-neuroinflammatory activity, combined with BDNF upregulation, positions Selank as a compound of significant interest in neuroprotection research.

6. Immune System Support and Cytokine Regulation

Derived from the immunoactive peptide tuftsin, Selank exerts measurable effects on the immune system through cytokine modulation, enhancement of macrophage phagocytic activity, and regulation of T-lymphocyte function. Studies have shown that Selank normalises immune responses that have been dysregulated by chronic stress, supporting the restoration of immune competence in individuals whose immune function has been compromised by prolonged psychological burden. This mind-immune axis activity is a dimension of Selank’s pharmacology with few parallels in other nootropic or anxiolytic compounds.

7. Improved Sleep Quality and Circadian Alignment

Through its anxiolytic, GABAergic, and serotonergic mechanisms, Selank supports the neurochemical conditions conducive to healthy sleep onset and maintenance. Research subjects report faster sleep onset, deeper slow-wave sleep, and improved sleep quality without the next-day grogginess associated with sedative hypnotics. By reducing the cognitive hyperarousal and rumination that frequently interfere with sleep in anxiety-prone individuals, Selank addresses a root cause of insomnia rather than simply suppressing consciousness.

Research History and Clinical Background

Development at the Russian Academy of Sciences

Selank was developed through a collaborative research programme between the Institute of Molecular Genetics of the Russian Academy of Sciences and the Zakusov Institute of Pharmacology in Moscow. The research programme began in the 1990s with the objective of creating a next-generation anxiolytic that could address the limitations of benzodiazepines — primarily their sedative, amnestic, and dependence-producing properties. The result was a class of tuftsin analogues, of which Selank emerged as the lead compound with the most favourable safety and efficacy profile.

Regulatory Approval and Clinical Use

Selank has been approved by the Russian Ministry of Health as a pharmaceutical medication for the treatment of generalised anxiety disorder (GAD) and asthenia. It has been in clinical use in Russia and Ukraine for over two decades, with a well-established safety record accumulated from thousands of patients. This regulatory approval and clinical track record sets Selank apart from many research peptides that lack equivalent clinical validation — it is not merely a preclinical compound but a proven pharmaceutical with approved human use in its country of origin.

Key Findings from Published Research

Highlights from the published scientific literature on Selank include:

• Anxiolytic efficacy comparable to benzodiazepines without sedation, tolerance, or dependence (Semenova et al.)
  • Significant enhancement of working memory and spatial learning in preclinical models
  • Upregulation of BDNF expression in hippocampal and cortical neurons
  • Inhibition of enkephalin-degrading enzymes, extending endogenous opioid peptide activity
  • Normalisation of IL-6 and other cytokine profiles dysregulated by chronic stress
  • Anxiolytic effects sustained over multi-week treatment courses without tolerance development
  • Enhancement of cognitive performance in patients with mild cognitive impairment (MCI)

  Research Dosage and Administration Protocols

  Selank 5mg is provided as a lyophilized powder for reconstitution. It may be administered subcutaneously or intranasally depending on the research protocol. The following guidance is based on published clinical data and established research community protocols:

  • Standard Research Dose: 250–500mcg (0.25–0.5mg) per administration via subcutaneous injection
  • Intranasal Dose: 400mcg (2 drops of a 0.15% solution) per nostril, up to 3 times daily — consistent with approved Russian clinical protocol
  • Cycle Length: 10–14 days per course; repeat courses after a 1–2 week rest period
  • Reconstitution: Reconstitute with 1–2ml bacteriostatic water; store at 2–8°C after reconstitution
  • Stability: Lyophilized powder stable at -20°C for up to 24 months; use reconstituted solution within 14 days
  • Stacking Consideration: Commonly researched alongside Semax (another Russian neuropeptide) for complementary nootropic and anxiolytic effects

  Selank vs Semax vs Benzodiazepines — How Does It Compare?

  Understanding how Selank compares to related compounds and conventional medications helps clarify its unique research value:

  • Selank vs Semax: Both are Russian neuropeptides with nootropic properties. Semax is primarily a cognitive enhancer and ACTH analogue with strong focus and energy effects; Selank is more balanced, with pronounced anxiolytic activity alongside its nootropic benefits. They are frequently researched together for complementary effects
  • Selank vs Benzodiazepines: Benzodiazepines (diazepam, alprazolam, clonazepam) produce anxiety relief through direct GABA-A positive allosteric modulation but cause sedation, memory impairment, motor dysfunction, and physical dependence. Selank produces anxiety relief without any of these adverse effects — a fundamental pharmacological advantage
  • • Selank vs SSRIs: SSRIs take 4–6 weeks to reach therapeutic effect, often cause emotional blunting, sexual dysfunction, and withdrawal syndrome on discontinuation. Selank’s anxiolytic effects are rapid-onset and do not involve serotonin reuptake inhibition, making its side-effect and withdrawal profile significantly cleaner
    • Selank vs Buspirone: Buspirone is a non-benzodiazepine anxiolytic with slow onset and modest efficacy. Selank’s multi-mechanism action — GABAergic, serotonergic, dopaminergic, enkephalinergic, and immunomodulatory — provides broader and more robust anxiolytic coverage
    • Selank vs L-Theanine: L-Theanine is a mild anxiolytic amino acid with modest effects. Selank is a clinically approved pharmaceutical peptide with a substantially more potent and mechanistically complex pharmacological profile

    Product Specifications

    • Peptide Name: Selank (TP-7)
    • Amino Acid Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro
    • CAS Number: 129954-34-3
    • Molecular Formula: C₃₃H₅₇N₁₃O₉
    • Molecular Weight: 751.87 g/mol
    • Vial Size: 5mg lyophilized powder
    • Purity: ≥98% (HPLC and mass spectrometry verified)
    • Appearance: White to off-white lyophilized powder
    • Solubility: Soluble in bacteriostatic water or sterile saline
    • Intended Use: Research and laboratory purposes only

    Why Choose Our Selank 5mg?

    Our Selank 5mg is synthesised using advanced Fmoc solid-phase peptide synthesis (SPPS) with rigorous sequence verification at every production stage. The correct heptapeptide sequence — Thr-Lys-Pro-Arg-Pro-Gly-Pro — is confirmed by mass spectrometry analysis before batch release. Independent third-party HPLC testing verifies purity at 98% or above, and sterility testing ensures every vial meets the standards required for injectable research use.

    Our Quality Guarantee

    • ≥98% purity confirmed by independent third-party HPLC analysis
    • Correct sequence (Thr-Lys-Pro-Arg-Pro-Gly-Pro) verified by mass spectrometry
    • Sterile filtration and lyophilization under GMP-aligned controlled conditions
    • Tamper-evident sealed vials with full batch number traceability and CoA available on request
    • Cold-chain compatible packaging maintaining peptide integrity throughout transit
    • Discreet, professional worldwide shipping with temperature-protective packaging

Frequently Asked Questions About Selank 5mg

Is Selank addictive or habit-forming?

No. One of Selank’s most important pharmacological distinctions from conventional anxiolytics is its complete absence of addiction potential, tolerance development, and physical dependence. Unlike benzodiazepines, which produce GABA-A receptor downregulation with chronic use and cause severe withdrawal on discontinuation, Selank does not produce receptor desensitisation or dependence. Multiple clinical studies have confirmed that Selank can be used for extended periods and discontinued without withdrawal effects — a property that makes it a fundamentally safer research alternative to benzodiazepine-class compounds.

How quickly does Selank produce its anxiolytic effects?

Selank’s anxiolytic effects are notably rapid in onset compared to most pharmaceutical anxiolytics. Subcutaneous administration produces detectable anxiolytic effects within 15 to 30 minutes in most research subjects, with peak effects occurring within one to two hours. Intranasal administration, which bypasses the blood-brain barrier more rapidly through olfactory nerve transport, may produce even faster onset — sometimes within minutes. The duration of a single dose’s effects is typically four to six hours, making it suitable for acute anxiety management protocols as well as sustained daily administration cycles.

Can Selank be used alongside other nootropic peptides?

In research settings, Selank is frequently studied in combination with Semax — another Russian neuropeptide with complementary mechanisms. Semax provides strong cognitive stimulation and focus through ACTH receptor activation and BDNF upregulation, while Selank contributes anxiolytic balance and emotional stability. This combination is sometimes described as providing a calm focus — the cognitive enhancement of Semax without the potential overstimulation, modulated by Selank’s anxiolytic properties. Researchers should review the relevant literature and establish appropriate parameters when designing combination protocols.

What is the difference between Selank and Semax?

Selank and Semax are both synthetic neuropeptides developed in Russia with nootropic properties, but they have distinct primary mechanisms and benefit profiles. Semax is an ACTH (4-7) analogue that primarily enhances cognitive performance, concentration, and mental energy through melanocortin receptor activation and strong BDNF upregulation. Selank is a tuftsin analogue that primarily reduces anxiety and stress while also enhancing cognition, memory, and immune function. Semax is the more stimulating and cognitively focused of the two; Selank is the more calming and emotionally balancing. Many researchers use them together to achieve a comprehensive neurocognitive and anxiolytic profile.